Public-Private Partnerships in Drug Development for Underdeveloped Countries: An Interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division
In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler...
| Autor principal: | |
|---|---|
| Tipo de documento: | Electrónico Artículo |
| Lenguaje: | Inglés |
| Verificar disponibilidad: | HBZ Gateway |
| Journals Online & Print: | Gargar...
|
| Fernleihe: | Fernleihe für die Fachinformationsdienste |
| Publicado: |
Cambridge Univ. Press
2003
|
| En: |
Cambridge quarterly of healthcare ethics
Año: 2003, Volumen: 12, Número: 4, Páginas: 429-433 |
| Acceso en línea: |
Volltext (lizenzpflichtig) Volltext (lizenzpflichtig) |
MARC
| LEADER | 00000naa a22000002 4500 | ||
|---|---|---|---|
| 001 | 1827977434 | ||
| 003 | DE-627 | ||
| 005 | 20221220052648.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221220s2003 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1017/S0963180103124127 |2 doi | |
| 035 | |a (DE-627)1827977434 | ||
| 035 | |a (DE-599)KXP1827977434 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 1 |2 ssgn | ||
| 100 | 1 | |a Kushner, Thomasine |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Public-Private Partnerships in Drug Development for Underdeveloped Countries: An Interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division |
| 264 | 1 | |c 2003 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a In an effort to create a mechanism for addressing a critical need of providing medicines for economically developing countries, the Chiron Corporation and the Global Alliance for TB Drug Development have entered into an innovative public-private partnership. In the following interview, Craig Wheeler discusses the origins and nature of this agreement that could set a pattern for how corporations and nonprofit organizations can work together in drug development. | ||
| 601 | |a Interview | ||
| 773 | 0 | 8 | |i Enthalten in |t Cambridge quarterly of healthcare ethics |d Cambridge : Cambridge Univ. Press, 1992 |g 12(2003), 4, Seite 429-433 |h Online-Ressource |w (DE-627)306655039 |w (DE-600)1499985-7 |w (DE-576)081985010 |x 1469-2147 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2003 |g number:4 |g pages:429-433 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/S0963180103124127 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.cambridge.org/core/journals/cambridge-quarterly-of-healthcare-ethics/article/publicprivate-partnerships-in-drug-development-for-underdeveloped-countries-an-interview-with-craig-wheeler-president-of-chirons-biopharmaceutical-division/37876A8BC874DBDA0FFB61116E0C1900 |x Verlag |z lizenzpflichtig |3 Volltext |
| 935 | |a mteo | ||
| 936 | u | w | |d 12 |j 2003 |e 4 |h 429-433 |
| 951 | |a AR | ||
| ELC | |a 1 | ||
| ITA | |a 1 |t 1 | ||
| LOK | |0 000 xxxxxcx a22 zn 4500 | ||
| LOK | |0 001 4235382349 | ||
| LOK | |0 003 DE-627 | ||
| LOK | |0 004 1827977434 | ||
| LOK | |0 005 20221220052648 | ||
| LOK | |0 008 221220||||||||||||||||ger||||||| | ||
| LOK | |0 035 |a (DE-Tue135)IxTheo#2022-12-06#BF2419795E312967CF42AC0D5BA1CED6A165D0B8 | ||
| LOK | |0 040 |a DE-Tue135 |c DE-627 |d DE-Tue135 | ||
| LOK | |0 092 |o n | ||
| LOK | |0 852 |a DE-Tue135 | ||
| LOK | |0 852 1 |9 00 | ||
| LOK | |0 935 |a ixzs |a ixrk |a zota | ||
| ORI | |a SA-MARC-ixtheoa001.raw | ||